Relative dose intensity of systemic chemotherapy in an outpatient cancer center


  • Christine Uptigrove Sparrow Health System
  • Kari Vavra Sparrow Health System
  • Claire Saadeh Sparrow Health System
  • Gordan Srkalovic Sparrow Cancer Center, Sparrow Health System, Lansing, MI, Michigan State University College of Human Medicine, East Lansing, MI


Drug therapy, Chemotherapy, Dose intensity


Objective. This study was undertaken to determine the averagerelative dose intensity (RDI) of chemotherapy administeredto patients in a community-based outpatient cancercenter. Methods. A retrospective review of medical recordsin an outpatient cancer center was conducted for patientsinitiating systemic chemotherapy in 2007 for a diagnosis oflymphoma, breast, lung, ovary, or colon cancer. Eighty-fourrecords meeting the inclusion criteria were reviewed for demographicinformation, primary tumor type, chemotherapyregimen, staging at diagnosis, presence of disease progression,and mortality status. Regimen data included: chemotherapeuticagents used, dosages administered, dates of administration,treatment intent (adjuvant vs. metastatic), andgranulocyte colony-stimulating factor (G-CSF) usage percycle. Mean summary statistics were calculated and averageRDI was analyzed. Results. The overall RDI at our institutionwas 83% (n=65). The RDI for those receiving adjuvant chemotherapywas 85% (n=51), whereas for those receiving chemotherapyfor metastatic disease the RDI was 76% (n=14).Fifty-four percent (n=35) of the regimens met or exceededthe recommended minimum goal RDI of > 85%. Conclusions.Overall the average RDI at our institution was 83%,slightly below the goal of ≥ 85%. Patients with potentially curablemalignancies receiving adjuvant chemotherapy reachedthe threshold RDI; however, areas for quality improvementexist at our institution.


Download data is not yet available.

Author Biographies

Christine Uptigrove, Sparrow Health System

Kari Vavra, Sparrow Health System

Claire Saadeh, Sparrow Health System

Gordan Srkalovic, Sparrow Cancer Center, Sparrow Health System, Lansing, MI, Michigan State University College of Human Medicine, East Lansing, MI


DeVita VT, Chu E. Principles of Medical Oncology. In: DeVita VT, Lawrence TS, Rosenberg SA, editors. Cancer: Principles and Practice of Oncology. 8th ed. Philadelphia: Lippincott; 2008. p. 340-342.

Foote M. The importance of planned dose of chemotherapy on time: do we need to change our clinical practice? Oncologist. 1998;3:365-8.

Lyman GH. Impact of chemotherapy dose intensity on cancer patient outcomes. J Natl Compr Canc Netw. 2009;7(1):99-108.

Hryniuk VM. The importance of dose intensity in the outcome of chemotherapy. In: Devita VT, Hellman S, Rosenberg SA, editors. Important Advances in Oncology. Philadelphia: Lippincott; 1988. p. 121-142.

Link BK, Budd GT, Scott S, Dickman E, Paul D, Lawless G, et al. Delivering adjuvant chemotherapy to women with early-stage breast carcinoma: current patterns of care. Cancer. 2001;92(6):1354-67.

Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol. 2003;21(24):4524-31.

Lyman GH, Dale DC, Friedberg J, Crawford J, Fisher RI. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin’s lymphoma: a nationwide study. J Clin Oncol. 2004;22(21):4302-11.

Norton L. Theoretical concepts and the emerging role of taxanes in adjuvant therapy. Oncologist. 2001;6(Suppl 3):30-5.

Picozzi VJ, Pohlman BL, Morrison VA, Lawless GD, Lee MW, Kerr RO, et al. Patterns of chemotherapy administration in patients with intermediate-grade non-Hodgkin’s lymphoma. Oncology (Williston Park). 2001;15(10):1296-306; discussion

-1, 1314.

Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003;21(8):1431-9.

Kwak LW, Halpern J, Olshen RA, Horning SJ. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol. 1990;8(6):963-77.

Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med. 1995;332(14):901-6.

Bonadonna G, Moliterni A, Zambetti M, Daidone MG, Pilotti S, Gianni L, et al. 30 years’ follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ.


NearSpace [homepage on the Internet]. Rohnert Park: NearSpace, Inc.; c2006 [cited 2010 Jun 9]. How the RDI Calculator Works. Available from:

Lenhart C. Relative dose intensity: improving cancer treatment and outcomes. Oncol Nurs Forum. 2005;32(4):757-64.

Griggs JJ, Sorbero ME, Lyman GH. Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med. 2005;165(11):1267-73.

Lyman GH. Chemotherapy dose intensity and quality cancer care. Oncology (Williston Park). 2006(14 Suppl 9):16-25.




How to Cite

Uptigrove, C., Vavra, K., Saadeh, C., & Srkalovic, G. (2010). Relative dose intensity of systemic chemotherapy in an outpatient cancer center. Acta Medica Academica, 39(2), 144–149. Retrieved from



Clinical Science

Most read articles by the same author(s)

Similar Articles

You may also start an advanced similarity search for this article.